Across TCGA pan-cancer cohorts, ZBTB46 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of ZBTB46’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ZBTB46 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ZBTB46 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.
CCRCC, HNSC, and LSCC are the cancer types where ZBTB46 tumor–normal differential expression is most reproducible.